Big news for scleroderma research: NIH Strategic Plan highlights autoimmune diseases 🔬
We are encouraged by the recent publication of the NIH‑Wide Strategic Plan for Autoimmune Disease Research for 2026–2030. At this particular time when funding for NIH administered research has come under unprecedented pressure, the SRF applauds the vision of this Plan, which signals renewed energy and investment in addressing autoimmune diseases.
Also, we are pleased to see that this Plan underscores the deep and profound impact that autoimmunity has on Americans, and disproportionately, American women.
“This Strategic Plan reflects a potentially important shift in federal research policy—explicitly acknowledging that diseases like scleroderma may be addressed best through coordinated disease‑specific investments combined with an overarching, systems‑level strategy that looks across the many autoimmune diseases,” says SRF Board Chair, Luke Evnin.
“Our sincere hope is that the Plan signals investment in this systems-level approach in addition to the NIH’s essential disease-specific funding—such as through its Scleroderma, Fibrosis, and Autoinflammatory Disease Program, which NIAMS administers,” he says.
Learn more about the strategic plan here: https://orwh.od.nih.gov/OADR-ORWH/Strategic-Planning-for-ADR
#NIH #news #sclerodermaresearch #scleroderma #SRFCure
